To estimate whether cell-free DNA is present in nonviable pregnancies and thus can be used in diagnostic evaluation in this setting.
We conducted a prospective cohort study of 50 participants at MedStar Washington Hospital Center, Washington, DC, between June 2013 and January 2014. Included were women with pregnancies complicated by missed abortion or fetal demise. All gestational ages were considered for study participation. Participants with fetal demise were offered the standard workup for fetal death per the American College of Obstetricians and Gynecologists. Maternal blood samples were processed to determine the presence of cell-free DNA, the corresponding fetal fractions, and genetic abnormalities.
Fifty samples from nonviable pregnancies were analyzed. The average clinical gestational age was 16.9 weeks (standard deviation 9.2). The mean maternal body mass index was 30.3 (standard deviation 9.1). Seventy-six percent (38/50) of samples yielded cell-free DNA results, that is, had fetal fractions within the detectable range of 3.7–65%. Among the 38, 76% (29) were classified as euploid, 21% (8) as trisomies, and 3% (1) as microdeletion. A cell-free DNA result was obtained more frequently at ultrasonographic gestational ages of 8 weeks or greater compared with less than 8 weeks (87.9% [n=29/33, 95% confidence interval (CI) 72.7–95.2; and 52.9%, n=9/17, 95% CI 31.0–73.8] of the time, respectively, P=.012). Time from demise was not associated with obtaining a result.
Among nonviable pregnancies, cell-free DNA is present in the maternal plasma with fetal fractions greater than 3.7% in more than three fourths of cases after an ultrasonographic gestational age of 8 weeks.
ClinicalTrials.gov, www.clinicaltrials.gov, NCT01916928.
Cell-free DNA can be isolated from maternal plasma in the presence of nonviable pregnancies.
Department of Obstetrics and Gynecology, MedStar Washington Hospital Center/MedStar Georgetown University Hospital, and the Department of Obstetrics and Gynecology, Johns Hopkins Medicine at Sibley Memorial Hospital, Washington, DC; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and Research and Development, Sequenom Laboratories, San Diego, California.
Corresponding author: Cecily A. Clark-Ganheart MD, Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, 110 Irving Street, NW, Suite 5B-39, Washington, DC 20010; e-mail: Ganheartmd@gmail.com.
Funded in part by Sequenom Laboratories, including funds for research personnel and specimen processing in-kind.
Presented at the 61st Annual Scientific Meeting of Society for Gynecologic Investigation, March 26–29, 2014, Florence, Italy.
Dr. Jensen participated in the writing of the methods that pertained to the processing of cell free-fetal DNA. Otherwise, Sequenom Laboratories was not involved in the design, execution, or analysis of this study which was investigator-initiated.
Financial Disclosure Dr. Clark-Ganheart received funding from Sequenom Laboratories to support this research endeavor. Dr. Jensen is an employee of Sequenom Laboratories and is a shareholder in Sequenom, Inc. The other authors did not report any potential conflicts of interest.